Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $150 million in 50 projects in seven countries.

150+

$million

Invested

50

innovative

Projects

7

different

Countries

14

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SutroVax’s new vaccine could be a game-changer in the prevention of Strep Throat infections and the spread of superbugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

11.26.19

Boston, MA

Live Webinar: GARDP/REVIVE – Innovation in point-of-care diagnostics for sepsis and bloodstream infections

CARB-X News

  • 11.20.2019  |  T2 Biosystems Announces Granting of CE-Mark for T2Resistance™ Panel full release

  • 11.06.2019  |  CARB-X funds Techulon to support the development of innovative nano therapeutics capable of killing drug-resistant bacteria by precisely targeting essential genes full release

  • 10.29.2019  |  CARB-X funds BioVersys to support the development of first-in-class anti-virulence small molecule drugs designed to disarm bacteria, opening the door for a paradigm shift in the treatment of drug resistant bacterial infections full release

See All News

In The News

  • 10.23.2019  |  Major discovery and characterization of new class of antibiotics against Gram-negative bacteria full story

  • 10.11.2019  |  Panel: Onus to stop antibiotic overuse is on prescribers, but advancements in new diagnostics, investments in drug development needed too full story

  • 10.11.2019  |  Drug-Resistant Infections: Confronting an Escalating Crisis full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.